Etryptamine

Etryptamine (also known as alpha-ethyltryptamine or αET) is a synthetic compound of the tryptamine class that was originally developed in the early 1960s as an antidepressant under the brand name Monase. It acts primarily as a non-hydrazine reversible inhibitor of monoamine oxidase and as a monoamine releasing agent for serotonin (predominantly), norepinephrine and dopamine. Etryptamine also functions as a serotonin receptor agonist and exhibits entactogenic and hallucinogenic properties similar to MDMA but with less pronounced stimulant effects. Its mechanism of action involves increasing synaptic concentrations of monoamines by both inhibiting their breakdown via MAO inhibition and promoting their release from presynaptic neurons. The drug was withdrawn from clinical use due to its association with agranulocytosis—a potentially fatal adverse effect—and is now classified as a Schedule I controlled substance in the United States due to its high abuse potential[1][3][4][5][6].

Brand names

Monase

Other names

etryptamineETRYPTAMINE (USAN US)ethyltryptamine3-(2-Aminobutyl)indole3-Indolylbutylamine